Document is current
Any future updates will be listed below
-
Authors
Kong, Ning
Xue, Yu
Mao, Li
Qian, Long
Guo, Hongtao
Hu, Jiankang
Yuan, Fenghong
Li, Rongbin
Duan, Xinwang
Yu, Jing
Gou, Wei
Yang, Lei
Wei, Hua
Li, Rongping
Xu, Qian
Luo, Tianhong
Zhang, Xu
Zou, Hejian https://orcid.org/0000-0001-9762-2663
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05936268 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial
https://doi.org/10.1007/s40744-025-00790-6
-
Funding
Funding for this research was provided by:
Changchun GeneScience Pharmaceutical Co., Ltd.
- License Information
-
More Information
Article History
Received: 30 June 2025
Accepted: 30 July 2025
First Online: 20 August 2025
Declarations
:
: Medical writing support was provided by Phoebe Kennedy, MSc, at Rude Health Consulting Ltd. This support was funded by Changchun GeneScience Pharmaceutical Co., Ltd. Manuscript preparation assistance was provided by Huiwen Jiao from Changchun GeneScience Pharmaceutical Co., Ltd.
: The study was conducted in accordance with international ethics guidelines, including the Declaration of Helsinki, and complied with Good Clinical Practice (GCP) standards. Ethical approval was obtained from the Ethics Committee of Huashan Hospital, Fudan University (Clinical Review No. 633, approved June 15, 2023), and from the institutional review boards of all participating centers (Supplementary Material, Table ). All participants provided written informed consent before enrollment. The study was registered at ClinicalTrials.gov (NCT05936268).
: Qian Xu, Tianhong Luo, and Xu Zhang are employees of Changchun GeneScience Pharmaceutical Co., Ltd. Ning Kong, Yu Xue, Li Mao, Long Qian, Hongtao Guo, Jiankang Hu, Fenghong Yuan, Rongbin Li, Xinwang Duan, Jing Yu, Wei Gou, Lei Yang, Hua Wei, Rongping Li, and Hejian Zou have nothing to disclose.
